RALLYBIO CORP (RLYB) Stock Price, Forecast & Analysis
NASDAQ:RLYB • US75120L1008
RLYB Key Statistics, Chart & Performance
The current stock price of RLYB is 5.06 USD. In the past month the price decreased by -5.96%. In the past year, price decreased by -16.11%.
RLYB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RLYB. When comparing the yearly performance of all stocks, RLYB is a bad performer in the overall market: 77.65% of all stocks are doing better.
RLYB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RLYB. While RLYB has a great health rating, there are worries on its profitability.
RLYB Financial Highlights
Over the last trailing twelve months RLYB reported a non-GAAP Earnings per Share(EPS) of -3.34. The EPS decreased by -108.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.88% | ||
| ROE | -22.41% | ||
| Debt/Equity | 0 |
RLYB Forecast & Estimates
For the next year, analysts expect an EPS growth of 71.04% and a revenue growth 8.72% for RLYB
RLYB Ownership
RLYB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 397.325B | ||
| AMGN | AMGEN INC | 16.63 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.62 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RLYB
Company Profile
Rallybio Corp is a US-based company operating in Biotechnology industry. The company is headquartered in New Haven, Connecticut and currently employs 15 full-time employees. The company went IPO on 2021-07-29. Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Company Info
RALLYBIO CORP
234 Church Street, Suite 1020
New Haven CONNECTICUT US
CEO: Martin W. Mackay
Employees: 15
Phone: 13026365400
RALLYBIO CORP / RLYB FAQ
What does RLYB do?
Rallybio Corp is a US-based company operating in Biotechnology industry. The company is headquartered in New Haven, Connecticut and currently employs 15 full-time employees. The company went IPO on 2021-07-29. Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
What is the current price of RLYB stock?
The current stock price of RLYB is 5.06 USD. The price increased by 6.53% in the last trading session.
Does RLYB stock pay dividends?
RLYB does not pay a dividend.
How is the ChartMill rating for RALLYBIO CORP?
RLYB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.